EP Vantage Medtech 2016 in Review
The annual EP Vantage Medtech 2016 in Review report offers analysis and expert commentary on M&A deals venture financing, initial public offerings and FDA approvals in the medtech sector during 2016.
2016 was a year of enormous change on the political stage. For the medical device industry, though, it was fairly quiet, with the pyrotechnics of 2015 a fast-fading memory.
Key findings include:
- The total value of M&A deals fell to $42bn, far below 2015’s total of $128bn
- Medtech companies raised a total of $3.7bn in 2016, down slightly from the year before, but the number of rounds continues to decline steeply
- At 38 in 2016, premarket approvals and humanitarian device exemptions saw a 25% decline from 2015; but de novo clearances were up, with 24 last year compared with 18 in 2015.